#JPM23: Fireside chat with Barry Greene: 'There's no straight line to success'
Endpoints News founder John Carroll sat down during JP Morgan with Sage CEO Barry Greene to talk about all things neuro. This transcript has been edited for brevity and clarity.
Barry Greene, the CEO of Sage Therapeutics, who after a 17-year run at Alnylam jumped and ended up as CEO of a company that’s now looking to field its first drug. And I wanted to talk to you a little bit about, first of all, what motivates you and what motivated you to do what you did here in going over to a different company at that stage in your career? What was going on? What was the driving factor that got you over to Sage?
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.